Peterhoff, David and Glueck, Vivian and Vogel, Matthias and Schuster, Philipp and Schuetz, Anja and Neubert, Philip and Albert, Veruschka and Frisch, Stefanie and Kiessling, Mara and Pervan, Philip and Werner, Maren and Ritter, Nicole and Babl, Leon and Deichner, Maria and Hanses, Frank and Lubnow, Matthias and Mueller, Thomas and Lunz, Dirk and Hitzenbichler, Florian and Audebert, Franz and Haehnel, Viola and Offner, Robert and Mueller, Martina and Schmid, Stephan and Burkhardt, Ralph and Glueck, Thomas and Koller, Michael and Niller, Hans Helmut and Graf, Bernhard and Salzberger, Bernd and Wenzel, Juergen J. and Jantsch, Jonathan and Gessner, Andre and Schmidt, Barbara and Wagner, Ralf (2021) A highly specific and sensitive serological assay detects SARS-CoV-2 antibody levels in COVID-19 patients that correlate with neutralization. INFECTION, 49 (1). pp. 75-82. ISSN 0300-8126, 1439-0973
Full text not available from this repository. (Request a copy)Abstract
Objective The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic challenges national health systems and the global economy. Monitoring of infection rates and seroprevalence can guide public health measures to combat the pandemic. This depends on reliable tests on active and former infections. Here, we set out to develop and validate a specific and sensitive enzyme linked immunosorbent assay (ELISA) for detection of anti-SARS-CoV-2 antibody levels. Methods In our ELISA, we used SARS-CoV-2 receptor-binding domain (RBD) and a stabilized version of the spike (S) ectodomain as antigens. We assessed sera from patients infected with seasonal coronaviruses, SARS-CoV-2 and controls. We determined and monitored IgM-, IgA- and IgG-antibody responses towards these antigens. In addition, for a panel of 22 sera, virus neutralization and ELISA parameters were measured and correlated. Results The RBD-based ELISA detected SARS-CoV-2-directed antibodies, did not cross-react with seasonal coronavirus antibodies and correlated with virus neutralization (R-2 = 0.89). Seroconversion started at 5 days after symptom onset and led to robust antibody levels at 10 days after symptom onset. We demonstrate high specificity (99.3%;N = 1000) and sensitivity (92% for IgA, 96% for IgG and 98% for IgM; > 10 days after PCR-proven infection;N = 53) in serum. Conclusions With the described RBD-based ELISA protocol, we provide a reliable test for seroepidemiological surveys. Due to high specificity and strong correlation with virus neutralization, the RBD ELISA holds great potential to become a preferred tool to assess thresholds of protective immunity after infection and vaccination.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | SARS CORONAVIRUS; PROTEIN; SPIKE; SARS-CoV-2; COVID-19; Antibody test; ELISA; Serology; Virus neutralization; Assay validation; Spike protein; S protein; Receptor binding domain |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Anästhesiologie Medicine > Lehrstuhl für Innere Medizin I Medicine > Lehrstuhl für Innere Medizin II Medicine > Lehrstuhl für Klinische Chemie und Laboratoriumsmedizin Medicine > Lehrstuhl für Medizinische Mikrobiologie und Hygiene Medicine > Zentren des Universitätsklinikums Regensburg > Zentrum für Klinische Studien |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 28 Feb 2022 06:43 |
| Last Modified: | 28 Feb 2022 06:43 |
| URI: | https://pred.uni-regensburg.de/id/eprint/43990 |
Actions (login required)
 |
View Item |
